HD-02, the Avicena Group Inc.’s proprietary drug candidate for the treatment of Huntington's disease (HD) recently received a USFDA orphan drug designation. In the journal Neurology, the company published the positive results of its Phase I/II data for HD-02.
The findings showed that the drug was safe and well-tolerated by patients at a dose of eight grams/day, while resulting in elevated serum and brain levels of creatine. Additional findings demonstrated that HD-02 reduced serum 8-hydroxy-2'-deoxyguanosine (serum 8OH2'dG) levels, which are markedly elevated in HD patients. Some researchers believe that this decrease in serum 8OH2'dG may suggest reduced oxidative injury in patients with Huntington's disease.
Such findings will be used by the researchers to design late-stage studies of HD-02 aimed at examining the drugs' ability to slow or halt the progression of Huntington's disease.
Source: Avicena Press Release
Comment Preview